A brief account of viral vectors and their promise for gene therapy
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Viral vectors are an efficient tool for gene transfection and account for many gene-therapy clinical trials.
“Viral vectors are a type of efficient tool for gene transfection and account for many gene-therapy clinical trials.[20, 25, 26]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Viral <scp>vector‐based</scp> gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269 · see citing works
“The primary reason of using a virus as a vector for gene delivery is to employ their natural capability of infecting cells and to efficiently shuttle gene materials of interest into host cells.(17) Major viral vector types used for in vivo gene therapies in the clinic include Ad, AAV, HSV, retrovirus, and lentivirus (…”
BackgroundNon-Viral in Vitro Gene Delivery: It is Now Time to Set the Bar!
Bono, N., Ponti, F., Mantovani, D., & Candiani, G. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020183 · Cited by 156 · see citing works
Treating Polymicrobial Infections in Chronic Diabetic Wounds
Buch, P. J., Chai, Y., & Goluch, E. D. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00091-18 · Cited by 147 · see citing works
“functional copies of genes to target cells (103, 104).”
BackgroundCationic lipids for gene delivery: many players, one goal
Ponti, F., Campolungo, M., Melchiori, C., Bono, N., & Candiani, G. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.105032 · Cited by 138 · see citing works
Damasceno, P. K. F., de Santana, T. A., Santos, G. C., Orge, I. D., Silva, D. N., Albuquerque, J. F., Golinelli, G., Grisendi, G., Pinelli, M., dos Santos, R. R., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00737 · Cited by 106 · see citing works
“Beyond those applications, AAV vectors have been used as favored vehicle for direct gene delivery to specific tissues (Finer and Glorioso, 2017).”
AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy
Pattali, R., Mou, Y.-C., & Li, X.-J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0085-4 · Cited by 82 · see citing works
DNA Vaccines: Their Formulations, Engineering and Delivery
Kozak, M., & Hu, J. (2024) · Vaccines · doi:10.3390/vaccines12010071 · Cited by 97 · see citing works
“Viral vectors were first elucidated in the 1970’s as a way to deliver new genetic material to cells [133].”
BackgroundInkjet printing of mammalian cells – Theory and applications
Kumar, P., Ebbens, S. J., & Zhao, X. (2021) · Bioprinting · doi:10.1016/j.bprint.2021.e00157 · Cited by 89 · see citing works
Dobrowsky, T., Gianni, D., Pieracci, J., & Suh, J. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100353 · Cited by 90 · see citing works
Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock
Martier, R., & Konstantinova, P. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.580179 · Cited by 87 · see citing works
A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management
Ghosh, S., Sinha, J. K., Ghosh, S. K., Sharma, H., Bhaskar, R., & Narayanan, K. B. (2023) · Brain Sciences · doi:10.3390/brainsci13091305 · Cited by 91 · see citing works
“Delivery methods, such as viral vectors, must be carefully engineered to ensure accurate and efficient gene transfer while minimizing immune responses and other adverse effects [207,208].”
BackgroundRNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82 · see citing works
Modulating gene regulation to treat genetic disorders
Matharu, N. K., & Ahituv, N. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0083-7 · Cited by 75 · see citing works
Yang, B., Zhang, X., Li, J., Tian, J., Wu, Y.-P., Yu, F., Wang, R., Wang, H., Zhang, D., Liu, Y., et al. (2019) · CCS Chemistry · doi:10.31635/ccschem.019.20180011 · Cited by 75 · see citing works
Nanomaterials for mRNA ‐based therapeutics: Challenges and opportunities
Li, D., Liu, Q., Yang, M., Xu, H., Zhu, M., Zhang, Y., Xu, J., Tian, C., Yao, J., Wang, L., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10492 · Cited by 71 · see citing works
“Viral vectors are very efficiency in mRNA transfection and are applied in clinical trials, such as Kymriah for chimeric antigen receptor (CAR) T immunotherapy on lymphoblastic leukemia.(23,24) However, viral vectors have disadvantages of potential carcinogenic, high immunogenic, limited gene packaging ability, and low…”
BackgroundApplication of Non-Viral Vectors in Drug Delivery and Gene Therapy
Ren, S., Wang, M., Wang, C., Wang, Y., Sun, C., Zeng, Z., Cui, H., & Zhao, X. (2021) · Polymers · doi:10.3390/polym13193307 · Cited by 65 · see citing works
Zhu, X., Ma, D., Yang, B., An, Q., Zhao, J., Gao, X., & Zhang, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03295-7 · Cited by 63 · see citing works
“AAV is one of the most promising gene transfer vectors because of its low immunogenicity, good safety, wide host cell range, and long-term expression of foreign genes [65, 66].”
BackgroundCardiac Fibrosis and Cardiac Fibroblast Lineage-Tracing: Recent Advances
Fu, X., Liu, Q., Li, C., Li, Y., & Wang, L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00416 · Cited by 54 · see citing works
“The development of gene therapies, especially the adeno-associated virus (AAV)-mediated gene therapy (Finer and Glorioso, 2017), has now made it possible to specifically manipulate gene expression in certain cell types.”
BackgroundScience and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction.
Cribbs, A. P., & Perera, S. (2017) · PubMed Central · Cited by 49 · see citing works
Nanotechnology-enabled gene delivery for cancer and other genetic diseases
Jiang, T., Gonzalez, K. M., Cordova, L. E., & Lu, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2200246 · Cited by 44 · see citing works
“Cells can be transfected efficiently because of the ability of utilizing the innate infectivity of wild-type viruses [30] to achieve a therapeutic”
BackgroundIntelligent Hydrogel-Assisted Hepatocellular Carcinoma Therapy
Tang, Z., Deng, L., Zhang, J., Jiang, T., Xiang, H., Chen, Y., Liu, H., Cai, Z., Cui, W., & Xiong, Y. (2024) · Research · doi:10.34133/research.0477 · Cited by 46 · see citing works
Ludwig, P. E., Freeman, S. C., & Janot, A. C. (2019) · International Journal of Retina and Vitreous · doi:10.1186/s40942-019-0158-y · Cited by 41 · see citing works
“AAV has emerged as a favored vector for direct gene delivery in vivo due to its lack of pathogenicity and ability to incorporate into a variety of tissues in a directed manner ( Table 2) ; one of its primary drawbacks is a limitation of packaged genetic material to 4.7 kb [45] .”
BackgroundInfluentialInnovative approaches in transforming microRNAs into therapeutic tools
Samad, A. F. A., & Kamaroddin, M. F. (2022) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1768 · Cited by 42 · see citing works
“RV vectors are important tools for the stable transfer of therapeutic miRNAs into dividing cells (Finer & Glorioso, 2017; Yang, 2015).”
BackgroundZhang, W., Hou, Y., Yin, S., Miao, Q., Lee, K., Zhou, X., & Wang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02580-8 · Cited by 43 · see citing works
Recent developments in gene therapy for Parkinson’s disease
Szunyogh, S., Carroll, E., & Wade‐Martins, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.030 · Cited by 35 · see citing works
“13 The safety and efficiency of adenovirus, lentivirus, AAV and HSV in humans have been shown extensively and these four viral vectors and their variants dominate the clinical landscape.”
Genetically modified immune cells targeting tumor antigens
Poorebrahim, M., Abazari, M. F., Sadeghi, S., Mahmoudi, R., Kheirollahi, A., Askari, H., Wickström, S. L., Poortahmasebi, V., Lundqvist, A., Kiessling, R. W., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107603 · Cited by 35 · see citing works
Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway
Dreismann, A. K., Hallam, T. M., Tam, L. C. S., Nguyen, C. V., Hughes, J. P., Ellis, S., & Harris, C. L. (2022) · Immunological Reviews · doi:10.1111/imr.13149 · Cited by 33 · see citing works
Bioinspired Spatiotemporal Management toward RNA Therapies
Ma, Y., Li, S., Lin, X., & Chen, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c08219 · Cited by 32 · see citing works
Chandler, M. R., Johnson, B., Khisamutdinov, E. F., Dobrovolskaia, M. A., Sztuba-Solińska, J., Salem, A. K., Breyne, K., Chammas, R. J., Walter, N. G., Contreras, L. M., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10240 · Cited by 32 · see citing works
miRNA Pathway Alteration in Response to Non-Coding RNA Delivery in Viral Vector-Based Gene Therapy
Savenkova, D. A., Makarova, A.-L. A., Shalik, I. K., & Yudkin, D. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314954 · Cited by 23 · see citing works
“The fact that viral vectors have become an essential part of gene therapy due to their natural abilities to infect mammalian cells and deliver genetic material effectively is apparent in the approved technologies and to individuals undergoing clinical trials [5].”
BackgroundPolymeric nanocarriers for therapeutic gene delivery
Zhang, J., Yang, X., Chang, Z., Zhu, W., Ma, Y., & He, H. (2025) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2025.101015 · Cited by 20 · see citing works
Tuning the Topological Landscape of DNA–Cyclodextrin Nanocomplexes by Molecular Design
Neva, T., Carbajo‐Gordillo, A. I., Benito, J. M., Lana, H., Marcelo, G., Mellet, C. O., de Ilarduya, C. T., Mendicuti, F., & Fernández, J. M. G. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002951 · Cited by 20 · see citing works
Delivery of therapeutic small interfering RNA: The current patent-based landscape
Chen, Y., Xiong, S.-H., Li, F., Kong, X., Ouyang, D., Zheng, Y., Yu, H., & Hu, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.06.011 · Cited by 19 · see citing works
“Viral vectors are mainly divided into adenoviruses and lentiviruses.(30)Non-viral vectors primarily include lipid-based carriers, polymer carriers,(31) inorganic carriers,(32) and biocarriers.”
BackgroundLorek, J. K., Isaksson, M., & Nilsson, B. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28932 · Cited by 19 · see citing works
“…(AAV) have attracted a lot of attention as one of the most favored in vivo viral ‐ based gene therapy technology over the last decade, competing with more established viral vector platforms including herpes simplex virus (HSV), adenovirus (Ad), and retro/lentivirus (Finer and Glorioso 2017).”
Exploring the Role of Gene Therapy for Neurological Disorders
Puranik, N., Yadav, D., Chauhan, P., Kwak, M., & Jin, J. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200917114101 · Cited by 17 · see citing works
Generation of CAR-T cells using lentiviral vectors
Poorebrahim, M., Quiros‐Fernandez, I., Fakhr, E., & Cid-Arregui, Á. (2022) · Methods in cell biology · doi:10.1016/bs.mcb.2021.07.001 · Cited by 16 · see citing works
Peptide-Based Vectors for Gene Delivery
Yang, J., & Luo, G. (2023) · Chemistry · doi:10.3390/chemistry5030116 · Cited by 16 · see citing works
VSeq-Toolkit: Comprehensive Computational Analysis of Viral Vectors in Gene Therapy
Afzal, S., Fronza, R., & Schmidt, M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.024 · Cited by 15 · see citing works
Advances in RNA-Based Therapeutics: Challenges and Innovations in RNA Delivery Systems
Liu, Y., Ou, Y., & Hou, L. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb47010022 · Cited by 15 · see citing works
mRNA vaccines and SiRNAs targeting cancer immunotherapy: challenges and opportunities
Lv, Z., & Dai, Y. (2025) · Discover Oncology · doi:10.1007/s12672-025-03070-5 · Cited by 14 · see citing works
Arumugam, S., Mary, B., Kumar, M., & Jayandharan, G. R. (2019) · Gene · doi:10.1016/j.gene.2019.144157 · Cited by 13 · see citing works
Membrane chromatography for AAV full capsid enrichment: Process development to scale up
Hernandez, J. H., Boenning, K., Kavara, A., & Schofield, M. (2024) · Journal of Chromatography B · doi:10.1016/j.jchromb.2024.124258 · Cited by 12 · see citing works
Potent and Targeted Sindbis Virus Platform for Immunotherapy of Ovarian Cancer
Opp, S., Hurtado, A. M., Pampeno, C. L., Lin, Z., & Meruelo, D. (2022) · Cells · doi:10.3390/cells12010077 · Cited by 11 · see citing works
“Most oncolytic vectors used today are administered intratumorally [77], owing to barriers which prevent systemic targeting, including dilution of the virus in the bloodstream, neutralization by anti-viral antibodies and complement proteins, virus particle sequestration in liver Kupffer cells and splenic macrophages, a…”
BackgroundGam, R., Sung, M. K., & Pandurangan, A. P. (2019) · Cells · doi:10.3390/cells8101189 · Cited by 10 · see citing works
“This has made it possible for the viral genome to be edited via molecular cloning and thus give rise to modified versions capable of directing a wide array of genetic functions within the host cell [34].”
BackgroundSelen, A., Müllertz, A., Kesisoglou, F., Ho, R. J. Y., Cook, J., Dickinson, P. A., & Flanagan, T. R. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00470-z · Cited by 10 · see citing works
Genetic Therapies for Sickle Cell Disease
Jayavaradhan, R., & Malik, P. (2018) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2018.01.008 · Cited by 8 · see citing works
A pH- and Bioreducible Cationic Copolymer with Amino Acids and Piperazines for Adenovirus Delivery
Thambi, T., Lee, J., Yoon, A. R., Kasala, D., & Yun, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030597 · Cited by 7 · see citing works
Wang, T., Hao, B., Xu, S., et al. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.119646 · Cited by 7 · see citing works
Zaitseva, T. S., Yang, G., Dionyssiou, D. D., Zamani, M., Sawamura, S. J., Yakubov, E., Ferguson, J., Hallett, R. L., Fleischmann, D., Paukshto, M. V., et al. (2020) · Regenerative Medicine · doi:10.2217/rme-2020-0023 · Cited by 7 · see citing works
“Most commonly, it employs DNAbased viral or plasmid vectors [7,8].”
BackgroundHeera, A., Kumar, T., Thakur, N., Gill, A. K., & Kumar, A. (2026) · Materials Today Chemistry · doi:10.1016/j.mtchem.2026.103568 · Cited by 5 · see citing works
Cationic lipids via multi-component Passerini reaction for non-viral gene delivery
Wang, R., Li, J., Chen, J., et al. (2024) · New Journal of Chemistry · doi:10.1039/d3nj05949a · Cited by 5 · see citing works
IRF7 drives macrophages to kill bacteria and improves septic outcomes via autophagy
Chen, G., Li, K., Luo, H., Zhao, L.-X., & Jiang, Y. (2025) · JCI Insight · doi:10.1172/jci.insight.189420 · Cited by 4 · see citing works
“To date, the 5 most commonly used strategies involve adenoviruses, lentiviruses, the herpes simplex virus, the vaccinia virus, and AAVs (45, 46).”
Synthesis and property of multifunctional non-viral gene vectors based on [12]aneN3
Wang, Q., Liu, X., Tang, F., & Lu, Z. (2022) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2022-0216 · Cited by 4 · see citing works
Metabolomics Analysis of Viral Therapeutics
Gu, H., Shi, X., Jasbi, P., & Patterson, J. S. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-1012-1_10 · Cited by 4 · see citing works
Selen, A., Müllertz, A., Kesisoglou, F., Ho, R. J. Y., Cook, J., Dickinson, P. A., & Flanagan, T. R. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00534-0 · Cited by 5 · see citing works
Wang, J., Chen, Z., Zhao, P., Wang, Y., Chen, J., & Lin, Q. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03077-0 · Cited by 4 · see citing works
Do the Biological Roles of Endogenous and Lysogenous Viruses Represent Faustian Bargains?
Hurst, C. J. (2022) · Advances in environmental microbiology · doi:10.1007/978-3-030-85395-2_4 · Cited by 3 · see citing works
Microneedle-mediated gene delivery: A promising approach for diverse disease treatment
Kenchegowda, M., Raj, G. K., Jyothi, S. L., Osmani, R. A. M., & Gangadharappa, H. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13881-2.00010-2 · Cited by 3 · see citing works
Review on the bioanalysis of non-virus-based gene therapeutics
Zhou, M., Zhang, X., Yan, H., Xing, L., Yi, T., & Shen, L. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2437418 · Cited by 3 · see citing works
Kotmakçı, M., Toncheva-Moncheva, N., Tarkavannezhad, S., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081012 · Cited by 2 · see citing works
“Initially, the viral vectors were developed and extensively evaluated both in vitro and in vivo due to their high transfection efficiency [8,9].”
Karimvand, S. K., Čuperlović‐Culf, M., Kamen, A., et al. (2025) · Bioengineering · doi:10.3390/bioengineering12040345 · Cited by 1 · see citing works
“Due to their inability to generate disease, AAVs are excellent candidates for gene therapy [1].”
Wang, Y., Zhu, D., & Yu, H. (2024) · Biomedical engineering · doi:10.5772/intechopen.1005186 · Cited by 1 · see citing works
Development and Deployment of Gene Therapies
Kili, S., & Chaffman, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-812034-7.00002-9 · Cited by 1 · see citing works
Resealed erythrocytes (RBCs) and their biomedical application
Shilpi, S., Rajpoot, K., Tekade, M., Sharma, M. C., Youngren-Ortiz, S. R., Deb, P. K., Chauhan, A. S., & Tekade, R. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814455-8.00016-5 · Cited by 11 · see citing works
Vectors in gene therapy: Benefit for glioblastoma patients
Carver, K., Negrete, D., Waterman, M., & Daddacha, W. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822527-1.00011-3 · Cited by 2 · see citing works
Vesiculovirus G protein-based stable cell lines for continuous lentiviral vector production
Tijani, M. (2018) · UCL Discovery (University College London) · Cited by 1 · see citing works
Design, Applications, and Processing of Synthetic Protein Nanoparticles
Becerra, D. Q. (2020) · Deep Blue (University of Michigan)
El debate ético y de regulación sobre el uso de CRISPR-Cas9 en la línea germinal humana
Amado, E. D., & Angulo, A. M. G. (2021) · Universitas Médica · doi:10.11144/javeriana.umed62-4.derc
“Sin embargo, su uso es controvertido, debido a efectos colaterales serios, que incluyen respuestas inmunológicas importantes contra el vector o la proteína, generación de cáncer e incluso la muerte en pacientes que participaron en estudios clínicos (15); pero gracias a mejoras significativas en la tecnología se han re…”
BackgroundGene therapy: advocacies, perspectives, and ethical provocations
Taliyan, R., Sukhija, R., Kothekar, A., Mishra, A., Nair, P. K. R., & Gurjar, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91924-1.00013-7
Karimvand, S. K., Čuperlović‐Culf, M., Kamen, A., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4594915/v1
Advanced drug delivery systems in the management of CNS disorders
Bidaliya, V., Alam, M. R., Bhratee, A., Kumar, M., Anand, P., Chawla, P. A., & Singh, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00020-2
Nucleic Acid-Based Systems for Regenerative Medicine
Martín, L., & Grzela, D. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_8
Abdollahpour, P., Shafizadeh, A., & Arefian, E. (2026) · Cytotechnology · doi:10.1007/s10616-026-00916-w
“Since then, viral vectors have rapidly developed and have been extensively studied to treat various conditions, especially cancers, by incorporating oncolytic vectors and developing viral-vectored cancer vaccines (Finer and Glorioso 2017; Seclì et al. 2023).”
Base editing approaches for the treatment of β-hemoglobinopathies
Antoniou, P. (2021) · theses.fr (ABES) · doi:10.70675/c4dddb32zf8aez4bc3z8cf8zce9a4e808265
Gene therapy for aging and longevity
Everts, S. P. A., Florea, M., & de Magalhães, J. P. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.05.007
Chang, T.-L., Ogundiran, A. I., Ivanov, A. I., Torain, G., Nekhai, S. A., & Chandran, P. L. (2026) · PLoS ONE · doi:10.1371/journal.pone.0357567
Zeng, X., Wang, Z., Cui, J., Wei, Y., Zhao, Q., Gu, B., & Gu, B. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108450
- Authors
- Finer, M., & Glorioso, J.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Glorioso, J
- ORCID
- Glorioso, J
- Venue
- Gene Therapy
- Published
- 2017-01
- Volume
- 24
- Issue
- 1
- Pages
- 1-2
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2581051743
- Cited by
- 79
- References
- 0
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 11 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 17 · 2019: 7 · 2018: 2 · 2017: 1
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- viral vectors, retroviral vectors, lentiviral vectors, reverse transcription, retroviral integration, pseudotyping, packaging cell lines, T cell engineering, cancer immunotherapy, microRNA regulation, insertional oncogenesis, history of gene therapy
- MeSH terms
- Animals, Genetic Vectors, Humans, Genetic Therapy, Gene Transfer Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
